| [Bowel perforation associated with bevacizumab therapy in recurrent ovarian cancers without bowel obstruction or bowel involvement]. | |
| | |
MedLine Citation:
|
PMID: 19011357 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Recent reports showed that bevacizumab, a humanized recombinant antibody binding to vascular endothelial growth factor (VEGF), harbored a significant activity in advanced or recurrent epithelial ovarian cancers. However, life-threatening complications including arterial thrombosis, pulmonary hemorrhage, and gastrointestinal perforation (GIP) are not negligible. A Japanese case of bowel perforation associated with bevacizumab treatment in heavily pretreated ovarian cancers is reported. The case affected with refractory ovarian cancer had no signs of bowel obstruction and bowel thickness which are now recognized as risk factors of GIP associated with bevacizumab. After obtaining a written informed consent, a combination of weekly paclitaxel and weekly bevacizumab was administered as the fourth-line therapy. After nine cycles of the regimen, the case developed GIP, although the recurrent tumor showed a stable disease. After conservative therapy for two months, the patient died. The case was severely pretreated; however, there seemed to be no risk factors for GIP. Therefore, we do recommend that special cautions are required for the bevacizumab- based chemotherapy, especially severely pretreated ovarian cancer patients. |
| | |
Authors:
|
Masashi Takano; Yoshihiro Kikuchi; Masafumi Kato; Tomoyuki Yoshikawa; Tsunekazu Kita |
Related Documents
:
|
20624317 - Elevation of sulfatides in ovarian cancer: an integrated transcriptomic and lipidomic a... 20034397 - Mucins in ovarian cancer diagnosis and therapy. 77377 - Does pregnancy protect against ovarian cancer? 20651987 - Microcell-mediated chromosome transfer identifies epb41l3 as a functional suppressor of... 12496917 - Conservative management of clinically localized prostate cancer. 20488607 - 'containment' as an analytical framework for understanding patient delay: a qualitative... |
Publication Detail:
|
Type: Case Reports; English Abstract; Journal Article |
Journal Detail:
|
Title: Gan to kagaku ryoho. Cancer & chemotherapy Volume: 35 ISSN: 0385-0684 ISO Abbreviation: Gan To Kagaku Ryoho Publication Date: 2008 Nov |
Date Detail:
|
Created Date: 2008-11-17 Completed Date: 2008-12-23 Revised Date: 2011-08-19 |
Medline Journal Info:
|
Nlm Unique ID: 7810034 Medline TA: Gan To Kagaku Ryoho Country: Japan |
Other Details:
|
Languages: jpn Pagination: 1981-4 Citation Subset: IM |
Affiliation:
|
Dept. of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Monoclonal
/
adverse effects*,
therapeutic use* Female Humans Intestinal Obstruction / radiography Intestinal Perforation / chemically induced*, radiography Middle Aged Neoplasm Recurrence, Local / drug therapy*, radiography Ovarian Neoplasms / drug therapy*, radiography, surgery Tomography, X-Ray Computed Treatment Failure |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/bevacizumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A case of unresectable advanced thymic carcinoma in an elderly woman responding to S-1 with good QOL...
Next Document: A case of primary unknown cancer responding to CDGP/S-1